CRC Research Finding Skip to content The CRC Digest Dihydroartemisinin targets KRASG12D to overcome immunotherapy resistance Anti-malaria drug selectively downregulates KRASG12D mutant protein and enhances regorafenib plus anti-PD-1 in preclinical liver metastasis models. (Cell Death & Disease) This content is informational only and does not constitute medical advice. Always consult your oncologist or
KRAS Mutations Predict Worse Outcomes After Liver Metastasis Surgery Skip to content The CRC Digest KRAS Mutations Predict Worse Outcomes After Liver Metastasis Surgery In 190 patients who had curative liver surgery for colorectal metastases, KRAS mutations (37.9% of patients) were associated with significantly worse overall and recurrence-free survival and more aggressive recurrence patterns. (Surgery Today) This content
French multicenter study to evaluate ctDNA after liver metastasis surgery Skip to content The CRC Digest French multicenter study to evaluate ctDNA after liver metastasis surgery The CLIMES PRODIGE 77 study will enroll 232 patients undergoing curative-intent liver metastasis resection to evaluate circulating tumor DNA as a biomarker for detecting minimal residual disease and predicting prognosis. (BMJ Open) This content
CRC Research Finding Skip to content The CRC Digest ▸ Multi-omics deep learning model predicts anti-EGFR therapy response in liver metastases A multi-center study developed a deep learning framework integrating multi-omics data to predict which RAS wild-type colorectal cancer liver metastases patients will benefit from cetuximab therapy, addressing primary resistance challenges. (Curr Cancer Drug